Hormones and cardiovascular health in women

Author
The ESHRE Capri Workshop GroupA meeting was organized by ESHRE Capri 31 August to 1 September 2005 with an unrestricted educational grant from Schering S.p.A. to discuss the above subject. The speakers included T.Farley Department of Reproductive Health and Research World Health Organization Geneva Switzerland B.Fauser University Medical Center Utrecht The Netherlands A.Glasier Family Planning and WW Services Edinburgh UK I.Greer Department of Obstetrics and Gynaecology University of Glasgow Gla
Published September 2006
Journal Human Reproduction Update
  See all Details

Abstract

Cardiovascular diseases (CVDs) may have their origin before birth: the combination of being small at birth and having an overly rich post-natal diet increases the likelihood of obesity and of acquiring a specific metabolic syndrome in adulthood that carries an increased risk of CVD. The incidence of CVD and mortality is very low in women of reproductive age but rises to a significant level in older women. In this article, we discuss CVD in relation to hormonal contraception, pregnancy and polycystic ovarian syndrome (PCOS) in younger women and menopause in older women. Women with PCOS have a higher risk of diabetes and hypertension, but studies to date have not shown an effect on CVD events. Use of combined hormonal contraception has only small effects on CVD because of the low baseline incidence of myocardial infarction (MI), stroke and venous thromboembolism (VTE) among young women. Women with existing risk factors or existing CVD, however, should consider alternative contraception. In pregnancy, CVD is rare, although, in the West, it now accounts for a significant proportion of maternal mortality as the frequency of obstetrical causes of mortality has substantially declined. The frequency of VTE is 15 per 10 000 during pregnancy and the post-partum period. In older women, menopause causes a slightly higher risk of MI after allowing for age, although there is substantial heterogeneity in the results of studies on menopause and age at menopause and MI. A larger effect might have been expected, because estrogen reduces the risk of developing atherosclerosis in premenopausal women, whereas in post-menopausal women who may have established atherosclerotic disease, estrogen increases the risk of myocardial disease through the effects on plaque stability and clot formation. Recent trial results indicate that hormone treatment in menopause does not favourably affect the risk of MI, stroke or other vascular disease. Thus, prevention of CVD should rely on diet and fitness, low-dose aspirin and treatment of hypertension, hyperglycaemia and hyperlipidaemia.

Reviews

Write Review

Saving... Saving... Cancel Save Cancel

Details

Title
Hormones and cardiovascular health in women
Author
The ESHRE Capri Workshop GroupA meeting was organized by ESHRE Capri 31 August to 1 September 2005 with an unrestricted educational grant from Schering S.p.A. to discuss the above subject. The speakers included T.Farley Department of Reproductive Health and Research World Health Organization Geneva Switzerland B.Fauser University Medical Center Utrecht The Netherlands A.Glasier Family Planning and WW Services Edinburgh UK I.Greer Department of Obstetrics and Gynaecology University of Glasgow Gla
Year
2006
Journal
Human Reproduction Update
Document Type
Research article
Language*
eng
Subjects
Cardiovascular Disease · Contraception · Menopause · Polycystic Ovary Syndrome · Pregnancy

Fields edited by Q-Sensei or Q-Sensei's users are marked with an asterisk (*).
This is Version 4 of this record. Q-Sensei Corp. added this version on November 3, 2009. It is an edited version of the original data import from IngentaConnect.com. View changes to the previous version or view the complete version history.
Q-Sensei Features Q-Sensei Facebook Fanpage Firefox Book Finder Plugin